Josephine A. Mauskopf
Vice President of Health Economics, RTI-HS
Josephine Mauskopf, PhD, MHA, has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf was previously vice president at MEDTAP International, department head of Economics Research at Burroughs Wellcome, and director of Pharmacoeconomics Research for anti-virals and anti-infectives at Glaxo Wellcome. She completed 8 years as editor in chief of Value in Health. She has presented her research at numerous national and international symposia, and has published extensively in journals.
PhD, Economics, Duke University; MHA, Health Administration, Duke University; MA, Physiology and Pharmacology, Duke University.
- Health Economics
- Burden of Illness Literature Reviews
- Economic Analyses of Health Care Interventions
- Health Policy Analyses
- May 14, 2015
RTI Health Solutions researchers contribute 43 poster and oral presentations at the ISPOR 20th Annual International Meeting
– News Release
- October 27, 2014
RTI Health Solutions researchers to discuss challenges, solutions for improving European health care at the ISPOR Annual European Congress
– News Release